{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:44:33Z","timestamp":1769755473615,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2019PH065"],"award-info":[{"award-number":["ZR2019PH065"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2019PH065"],"award-info":[{"award-number":["ZR2019PH065"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Innovation and Development Project of Taian city","award":["2020NS105"],"award-info":[{"award-number":["2020NS105"]}]},{"name":"Science and Technology Innovation and Development Project of Taian city","award":["2020NS105"],"award-info":[{"award-number":["2020NS105"]}]},{"name":"Science and Technology Innovation and Development Project of Taian city","award":["2020NS105"],"award-info":[{"award-number":["2020NS105"]}]},{"name":"Medical Science and Technology Development Program of Shandong Province","award":["2018WS140"],"award-info":[{"award-number":["2018WS140"]}]},{"name":"Medical Science and Technology Development Program of Shandong Province","award":["2018WS140"],"award-info":[{"award-number":["2018WS140"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Proliferative diabetic retinopathy (PDR) can seriously affect the vision and quality of life of patients. The present study aimed to evaluate the clinical effect of vitrectomy for PDR by observing visual recovery and postoperative complications and to explore the factors influencing low vision.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a case series observational study. Consecutive eyes of patients with PDR who underwent 23G vitrectomy in our hospital within one year (2019.11-2020.11) were collected and followed up for more than 2 years. Patients\u2019 visual acuity, surgical complications and management were collected before the operation and during the follow-up. Decimal visual acuity was recorded and converted to the logarithm of the minimal angle of resolution (logMAR) for statistical analysis. Excel was used to establish a database, and SPSS 22.0 statistical software was used for data analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 127 patients and 174 eyes were included in the study. The mean age was 57.8 years. The best corrected visual acuity (BCVA) was &lt;\u20090.3 in 89.7% of eyes before surgery and \u2265\u20090.3 in 48.3% of eyes after surgery. Among 174 eyes, visual acuity improved in 83.3%. There was no change in 8.6% of eyes, while 8.1% of eyes had decreased visual acuity after surgery. The average logMAR visual acuity was 1.5\u2009\u00b1\u20090.7 before surgery and 0.7\u2009\u00b1\u20090.6 after surgery, indicating significant improvement (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Logistic regression analysis showed that intraoperative silicone oil filling and postoperative complication were significant risk factors for postoperative low vision, while preoperative pseudophakic lens and postoperative intra vitreal injection of anti-VEGF were protective factors for vision recovery (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). The incidence of postoperative complications was 15.5%, top three of which were vitreous haemorrhage, neovascular glaucoma and traction retinal detachment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Vitrectomy is safe and effective in the treatment of PDR with few complication. Postoperative intra vitreal injection of anti-VEGF is a protective factor for vision recovery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The trial registration number is ChiCRT2100051628, and the date of registration was September 28, 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-023-03071-4","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T11:01:54Z","timestamp":1688986914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Influencing factors of low vision 2 years after vitrectomy for proliferative diabetic retinopathy: an observational study"],"prefix":"10.1186","volume":"23","author":[{"given":"Shengxia","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhong","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijing","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"issue":"01","key":"3071_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3760\/cma.j.cn511434-20201224-00634","volume":"37","author":"YN Hui","year":"2021","unstructured":"Hui YN. Accurate evaluation and control of diabetic retinopathy. Chin J Fundus Disease. 2021;37(01):1\u20134. https:\/\/doi.org\/10.3760\/cma.j.cn511434-20201224-00634","journal-title":"Chin J Fundus Disease"},{"key":"3071_CR2","doi-asserted-by":"publisher","first-page":"m997","DOI":"10.1136\/bmj.m997","volume":"369","author":"Y Li","year":"2020","unstructured":"Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the american Diabetes Association: national cross sectional study. BMJ. 2020;369:m997. https:\/\/doi.org\/10.1136\/bmj.m997. Published 2020 Apr 28.","journal-title":"BMJ"},{"issue":"2","key":"3071_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.18240\/ijo.2019.02.19","volume":"12","author":"QH Yang","year":"2019","unstructured":"Yang QH, Zhang Y, Zhang XM, et al. Prevalence of diabetic retinopathy, proliferative diabetic retinopathy and non-proliferative diabetic retinopathy in asian T2DM patients: a systematic review and meta-analysis. Int J Ophthalmol. 2019;12(2):302\u201311. https:\/\/doi.org\/10.18240\/ijo.2019.02.19","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"3071_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/aos.14482","volume":"99","author":"V Schreur","year":"2021","unstructured":"Schreur V, Brouwers J, Van Huet RAC, et al. Long-term outcomes of vitrectomy for proliferative diabetic retinopathy. Acta Ophthalmol. 2021;99(1):83\u20139. https:\/\/doi.org\/10.1111\/aos.14482","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"3071_CR5","doi-asserted-by":"publisher","first-page":"e0244281","DOI":"10.1371\/journal.pone.0244281","volume":"16","author":"K Nishi","year":"2021","unstructured":"Nishi K, Nishitsuka K, Yamamoto T, et al. Factors correlated with visual outcomes at two and four years after vitreous surgery for proliferative diabetic retinopathy. PLoS ONE. 2021;16(1):e0244281. https:\/\/doi.org\/10.1371\/journal.pone.0244281. Published 2021 Jan 14.","journal-title":"PLoS ONE"},{"issue":"10","key":"3071_CR6","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/s0161-6420(01)00590-5","volume":"108","author":"L Hyman","year":"2001","unstructured":"Hyman L, Wu SY, Connell AM, et al. Prevalence and causes of visual impairment in the Barbados Eye Study. Ophthalmology. 2001;108(10):1751\u20136. https:\/\/doi.org\/10.1016\/s0161-6420(01)00590-5","journal-title":"Ophthalmology"},{"issue":"6","key":"3071_CR7","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1177\/112067210701700614","volume":"17","author":"YangCM ShenYD","year":"2007","unstructured":"ShenYD YangCM. Extended silicone oil tamponade in primary vitrectomy for complex retinal detachment in proliferative diabetic retinopathy: a long-term follow-up study. Eur J Ophthalmol. 2007;17(6):954\u201360. https:\/\/doi.org\/10.1177\/112067210701700614","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"3071_CR8","doi-asserted-by":"publisher","first-page":"e864","DOI":"10.1111\/aos.15055","volume":"100","author":"FJ Valent\u00edn-Bravo","year":"2022","unstructured":"Valent\u00edn-Bravo FJ, Garc\u00eda-Onrubia L, Andr\u00e9s-Iglesias C, et al. Complications associated with the use of silicone oil in vitreoretinal surgery: a systemic review and meta-analysis. Acta Ophthalmol. 2022;100(4):e864\u201380. https:\/\/doi.org\/10.1111\/aos.15055","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"3071_CR9","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1007\/s10792-020-01418-0","volume":"40","author":"F Pichi","year":"2020","unstructured":"Pichi F, Hay S, Abboud EB. Inner retinal toxicity due to silicone oil: a case series and review of the literature. Int Ophthalmol. 2020;40(9):2413\u201322. https:\/\/doi.org\/10.1007\/s10792-020-01418-0","journal-title":"Int Ophthalmol"},{"key":"3071_CR10","doi-asserted-by":"publisher","unstructured":"Karaca U, Kucukevcilioglu M, Durukan AH, Akincioglu D. The effect of longstanding silicone oil on retina choroid and optic nerve in eyes with retinal detachment: an optical coherence tomography study. BMC Ophthalmol. 2022;22(1):11. Published 2022 Jan 5. https:\/\/doi.org\/10.1186\/s12886-021-02239-0","DOI":"10.1186\/s12886-021-02239-0"},{"key":"3071_CR11","doi-asserted-by":"publisher","unstructured":"Cruz-I\u00f1igoYJ. Acab\u00e1LA, BerrocalMH.Surgical management of retinal diseases: proliferative diabetic retinopathy and traction retinal detachment.Dev Ophthalmol, 2014, 54:196\u2013203. https:\/\/doi.org\/10.1159\/000360467","DOI":"10.1159\/000360467"},{"issue":"09","key":"3071_CR12","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3760\/cma.j.cn115989-20200307-00150","volume":"39","author":"XE Fan","year":"2021","unstructured":"Fan XE, Ke YF, Ren XJ, et al. Risk factors of vitreous hemorrhage after vitrectomy in proliferative diabetic retinopathy. Chin J Experimental Ophthalmolog. 2021;39(09):803\u201310. https:\/\/doi.org\/10.3760\/cma.j.cn115989-20200307-00150","journal-title":"Chin J Experimental Ophthalmolog"},{"issue":"11","key":"3071_CR13","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.ophtha.2011.03.036","volume":"118","author":"J Ahn","year":"2011","unstructured":"Ahn J, Woo SJ, Chung H, et al. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology. 2011;118(11):2218\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2011.03.036","journal-title":"Ophthalmology"},{"issue":"10","key":"3071_CR14","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1097\/IAE.0000000000000723","volume":"35","author":"MP Simunovic","year":"2015","unstructured":"Simunovic MP, Maberley DA. Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy: a systematic review and meta-analysis. Retina. 2015;35(10):1931\u201342. https:\/\/doi.org\/10.1097\/IAE.0000000000000723","journal-title":"Retina"},{"key":"3071_CR15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/bjophthalmol-2017-311344","volume":"102","author":"XY Zhao","year":"2018","unstructured":"Zhao XY, Xia S, Chen YX. Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials. Br J Ophthalmol. 2018;102:1077\u201385.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"3071_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41433-021-01474-5","volume":"36","author":"GH Chen","year":"2022","unstructured":"Chen GH, Tzekov R, Mao SH, et al. Intravitreal conbercept as an adjuvant in vitrectomy for proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials. Eye (Lond). 2022;36(3):619\u201326. https:\/\/doi.org\/10.1038\/s41433-021-01474-5","journal-title":"Eye (Lond)"},{"issue":"7","key":"3071_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/IJG.0b013e31824d514a","volume":"22","author":"InataniM GotoA","year":"2013","unstructured":"GotoA InataniM. Frequency and risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy. J Glaucoma. 2013;22(7):572\u20136. https:\/\/doi.org\/10.1097\/IJG.0b013e31824d514a","journal-title":"J Glaucoma"},{"issue":"10","key":"3071_CR18","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.1167\/iovs.12-10367","volume":"53","author":"UsuiY WakabayashiY","year":"2012","unstructured":"WakabayashiY UsuiY. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy[J]. Invest Ophthalmol Vis Sci. 2012;53(10):6403\u201310. https:\/\/doi.org\/10.1167\/iovs.12-10367","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"3071_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3760\/cma.j.cn511434-20200623-00302","volume":"37","author":"XE Fan","year":"2021","unstructured":"Fan XE, Ke YF, Ren XJ, et al. Risk factors of neovascular glaucoma after minimally invasive vitrectomy for proliferative diabetic retinopathy. Chin J fundus ophthalmosis. 2021;37(1):15\u201320. https:\/\/doi.org\/10.3760\/cma.j.cn511434-20200623-00302","journal-title":"Chin J fundus ophthalmosis"},{"issue":"4","key":"3071_CR20","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/aos.13019","volume":"94","author":"ZouC LuQ","year":"2016","unstructured":"LuQ ZouC. Preoperative intravitreal injection of ranibizumab for patients with severe proliferative diabetic retinopathy contributes to a decreased risk of postoperative neovascular glaucoma. Acta Ophthalmol. 2016;94(4):414\u20135. https:\/\/doi.org\/10.1111\/aos.13019","journal-title":"Acta Ophthalmol"},{"key":"3071_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajo.2020.09.051","volume":"223","author":"M Ohlhausen","year":"2021","unstructured":"Ohlhausen M, Payne C, Greenlee T, et al. Impact and characterization of delayed Pan-Retinal Photocoagulation in proliferative Diabetic Retinopathy. Am J Ophthalmol. 2021;223:267\u201374. https:\/\/doi.org\/10.1016\/j.ajo.2020.09.051","journal-title":"Am J Ophthalmol"},{"issue":"10085","key":"3071_CR22","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","volume":"389","author":"S Sivaprasad","year":"2017","unstructured":"Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389(10085):2193\u2013203. https:\/\/doi.org\/10.1016\/S0140-6736(17)31193-5","journal-title":"Lancet"},{"key":"3071_CR23","doi-asserted-by":"publisher","unstructured":"Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial [published correction appears in JAMA[J]. 2016 Mar 1;315(9):944] [published correction appears in JAMA. 2019 Mar 12;321(10):1008]. JAMA. 2015;314(20):2137\u20132146. https:\/\/doi.org\/10.1001\/jama.2015.15217","DOI":"10.1001\/jama.2015.15217"},{"issue":"10","key":"3071_CR24","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","volume":"136","author":"JG Gross","year":"2018","unstructured":"Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for proliferative Diabetic Retinopathy: a Randomized Clinical Trial [published correction appears in JAMA Ophthalmol. 2019 Apr 1;137(4):467]. JAMA Ophthalmol. 2018;136(10):1138\u201348. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.3255","journal-title":"JAMA Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-023-03071-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-023-03071-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-023-03071-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T11:05:01Z","timestamp":1688987101000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-023-03071-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3071"],"URL":"https:\/\/doi.org\/10.1186\/s12886-023-03071-4","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"assertion":[{"value":"9 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The work described had been performed in accordance with the Declaration of Helsinki and had been approved by ethics committee of Taian City Central hospital (Approval number2021-06-82). The trial registration number is ChiCRT2100051628 and the date of registration was September 28, 2021. Informed consent has been obtained from all subjects and\/or their legal guardian(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. For our manuscript doesn\u2019t include details, images, or videos relating to an individual person.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"309"}}